BPMUF: AI 评分 58/100 — AI 分析 (4月 2026)

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company focused on developing products in oncology and anti-infectives. Its key products include Cresemba, an antifungal, and Zevtera, an antibiotic, with ongoing clinical trials to expand their applications and market reach.

Key Facts: AI Score: 58/100 Sector: Healthcare

公司概况

概要：

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in oncology and anti-infectives, offering treatments like Cresemba and Zevtera. With a 17.9% profit margin and a beta of 0.46, the company focuses on addressing unmet medical needs through ongoing clinical trials and strategic product development within the biotechnology sector.

BPMUF是做什么的？

Founded in 2000 and headquartered in Basel, Switzerland, Basilea Pharmaceutica AG is a biopharmaceutical company dedicated to developing and commercializing innovative products that address critical medical needs in oncology and anti-infectives. The company's portfolio includes Cresemba, an intravenous and oral azole antifungal drug used to treat invasive aspergillosis and mucormycosis. Cresemba is available in the United States and the European Union, and is currently in Phase III clinical trials in Japan for invasive fungal infections. Another key product is Zevtera, an antibiotic used for treating community and hospital-acquired pneumonia. Zevtera is also undergoing Phase III clinical trials for acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. Basilea is also developing Derazantinib, a small molecule inhibitor in Phase 2 clinical trial for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. Additionally, they are developing Lisavanbulin, a tumor checkpoint controller drug. Basilea's strategic focus on these therapeutic areas positions it to capitalize on the growing demand for novel treatments in oncology and infectious diseases.

BPMUF的投资论点是什么？

Basilea Pharmaceutica AG presents a compelling investment case due to its established products and promising pipeline. With a market capitalization of $0.87 billion and a P/E ratio of 19.42, the company demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of Cresemba and Zevtera, as well as the advancement of Derazantinib and Lisavanbulin through clinical trials. The company's 74.3% gross margin indicates strong pricing power and efficient operations. Upcoming clinical trial results and potential regulatory approvals for its pipeline candidates serve as significant growth catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

BPMUF在哪个行业运营？

Basilea Pharmaceutica AG operates within the biotechnology industry, which is characterized by rapid innovation and high regulatory scrutiny. The market for anti-infectives and oncology drugs is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Basilea differentiates itself through its focus on specific therapeutic areas and its pipeline of novel drug candidates. The biotechnology industry is expected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and drug delivery technologies.

Biotechnology

Healthcare

BPMUF有哪些增长机遇？

Expansion of Cresemba's Market Reach: Cresemba, Basilea's antifungal drug, has the potential for significant growth through geographic expansion and label extensions. The global market for antifungal drugs is projected to reach $17.5 billion by 2028. Securing regulatory approvals in additional markets, such as Japan, and expanding its use to treat other fungal infections could drive substantial revenue growth for Basilea.
Advancement of Derazantinib in Oncology: Derazantinib, a small molecule inhibitor, is currently in Phase 2 clinical trials for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. The oncology market is one of the largest and fastest-growing segments in the pharmaceutical industry. Positive clinical trial results and subsequent regulatory approval could position Derazantinib as a valuable asset in Basilea's oncology portfolio, addressing a significant unmet medical need.
Development of Lisavanbulin as a Tumor Checkpoint Controller: Lisavanbulin, a tumor checkpoint controller drug, represents a novel approach to cancer treatment. The market for immunotherapies and checkpoint inhibitors is experiencing rapid growth. Successful development and commercialization of Lisavanbulin could provide Basilea with a competitive advantage in the oncology space, capturing a significant share of the immunotherapy market.
Lifecycle Management of Zevtera: Zevtera, Basilea's antibiotic, is currently in Phase III clinical trials for acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. Expanding the indications for Zevtera through successful clinical trials and regulatory approvals can extend its market exclusivity and drive revenue growth. The increasing prevalence of antibiotic-resistant bacteria underscores the need for new and effective antibiotics, creating a favorable market environment for Zevtera.
Strategic Partnerships and Acquisitions: Basilea can pursue strategic partnerships and acquisitions to expand its pipeline and market reach. Collaborating with other biotechnology and pharmaceutical companies can provide access to new technologies, drug candidates, and markets. Acquiring complementary assets can strengthen Basilea's competitive position and accelerate its growth trajectory. These strategic initiatives can enhance Basilea's long-term value and create synergies across its operations.

Market Cap of $0.87 billion reflects investor confidence in Basilea's pipeline and commercial products.
P/E ratio of 19.42 indicates a reasonable valuation compared to its earnings.
Profit Margin of 17.9% demonstrates efficient operations and profitability.
Gross Margin of 74.3% showcases strong pricing power and cost management.
Beta of 0.46 suggests lower volatility compared to the overall market, making it a potentially stable investment.

BPMUF提供哪些产品和服务？

Develop and commercialize pharmaceutical products.
Focus on oncology and anti-infectives therapeutic areas.
Offer Cresemba for the treatment of invasive aspergillosis and mucormycosis.
Provide Zevtera for the treatment of community and hospital-acquired pneumonia.
Engage in clinical trials for new drug candidates.
Develop Derazantinib for bile duct, bladder, and stomach cancer.
Develop Lisavanbulin as a tumor checkpoint controller drug.

BPMUF如何赚钱？

Develop and license pharmaceutical products.
Generate revenue through product sales.
Invest in research and development to expand product pipeline.
Partner with other companies for commercialization and distribution.

Hospitals and healthcare providers.
Patients with fungal infections and pneumonia.
Oncology patients.
Pharmaceutical distributors.

Patented pharmaceutical products.
Specialized expertise in oncology and anti-infectives.
Established distribution network.
Strong brand reputation.

什么因素可能推动BPMUF股价上涨？

Upcoming: Phase III clinical trial results for Cresemba in Japan for invasive fungal infections.
Upcoming: Phase III clinical trial results for Zevtera in acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia.
Ongoing: Phase 2 clinical trial progress for Derazantinib in bile duct cancer.
Ongoing: Phase ½ clinical trial progress for Derazantinib in bladder and stomach cancer.
Ongoing: Development progress of Lisavanbulin as a tumor checkpoint controller drug.

BPMUF的主要风险是什么？

Potential: Clinical trial failures for drug candidates.
Potential: Regulatory delays or rejections.
Ongoing: Competition from established pharmaceutical companies.
Ongoing: Patent expirations and generic drug entry.
Potential: Product liability claims.

BPMUF的核心优势是什么？

Specialized expertise in oncology and anti-infectives.
Commercialized products with established revenue streams.
Promising pipeline of drug candidates in clinical trials.
Strong gross margin.

BPMUF的劣势是什么？

Reliance on a limited number of products.
High R&D expenses.
Dependence on regulatory approvals.
Competition from larger pharmaceutical companies.

BPMUF有哪些机遇？

Expansion into new geographic markets.
Development of new drug candidates.
Strategic partnerships and acquisitions.
Lifecycle management of existing products.

BPMUF面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from generic drugs.
Patent expirations.

BPMUF的竞争对手是谁？

Bio-Japan R&D Co Ltd — Focuses on drug discovery and development. — (BJTRF)
Faron Pharmaceuticals Oy — Develops novel treatments for cancer and immune diseases. — (FOGCF)
Gensight Biologics SA — Develops gene therapies for retinal neurodegenerative diseases. — (GSGTF)
Inhibrx Inc — Develops a broad pipeline of novel biologic therapeutic candidates. — (INRLF)
MediciNova Inc — Focuses on developing novel small molecule therapeutics. — (MDCLF)

Key Metrics

MoonshotScore: 58/100

Company Profile

CEO: David Veitch
Headquarters: Allschwil, CH
Employees: 164
Founded: 2015

AI Insight

AI analysis pending for BPMUF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Basilea Pharmaceutica AG do?

Basilea Pharmaceutica AG is a biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products in the therapeutic areas of oncology and anti-infectives. The company's portfolio includes commercialized products such as Cresemba, an antifungal, and Zevtera, an antibiotic, which are marketed to hospitals and healthcare providers. Additionally, Basilea is actively engaged in clinical trials for new drug candidates, including Derazantinib for cancer treatment and Lisavanbulin as a tumor checkpoint controller, aiming to expand its product offerings and address unmet medical needs in these critical areas.

What do analysts say about BPMUF stock?

Analyst coverage of BPMUF is pending, but key valuation metrics to consider include its market capitalization of $0.87 billion and P/E ratio of 19.42. The company's growth prospects are tied to the continued commercial success of its existing products and the advancement of its pipeline candidates through clinical trials. Investors should monitor clinical trial results, regulatory approvals, and market dynamics to assess the potential upside and downside risks associated with BPMUF stock. A neutral stance is warranted until further analyst reports are available.

What are the main risks for BPMUF?

The main risks for Basilea Pharmaceutica AG include the potential for clinical trial failures, which could significantly impact the company's pipeline and future revenue prospects. Regulatory hurdles and delays in obtaining approvals for new drugs also pose a risk. Competition from larger pharmaceutical companies with greater resources and established market presence is another factor. Additionally, patent expirations and the entry of generic drugs could erode the company's market share and profitability. Product liability claims and adverse events related to its drugs also represent potential risks.